RxDoctor Payments Data

Misty Branam, DO

Internal Medicine · McAlester, OKNPI 1962660688

Payments from drug & device makers

$634in general payments, 2019–2025

Across 33 payments — averaging $19.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Mylan Specialty L.p.$125
  • Pfizer$105
  • Astellas Pharma US Inc$85
  • Sanofi-aventis U.S. LLC$44
  • GSK$41
  • Novo Nordisk$40
  • plus $194 from 8 others

What the payments were for

  • Food & beverage$54987%
  • Education$8513%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$634 in reported general payments places this provider in the 60th percentile of 840 internal medicine providers in Oklahoma.

See all internal medicine providers in Oklahoma

Medicare billing

Part B allowed, 2024
$90,047
Medicare patients
318
Services billed
1,311

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide89$110,525
EliquisApixaban123$86,429
JardianceEmpagliflozin71$82,332
Trelegy ElliptaFluticasone/Umeclidin/Vilanter63$78,715
JanuviaSitagliptin Phosphate48$50,708
MounjaroTirzepatide31$39,469
MyrbetriqMirabegron36$32,032
RybelsusSemaglutide19$25,949
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr19$16,838
TrulicityDulaglutide12$12,742
FarxigaDapagliflozin Propanediol13$7,903
Spiriva RespimatTiotropium Bromide13$7,740
Rosuvastatin Calcium353$6,595
Ezetimibe207$5,156
SymbicortBudesonide/Formoterol Fumarate14$4,547

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$40$136,474108 claims
GSKTrelegy Ellipta, Anoro Ellipta$41$95,55382 claims
Boehringer IngelheimJardiance, Spiriva Respimat$21$90,07284 claims
PfizerEliquis$105$86,429123 claims
Astellas Pharma US IncMyrbetriq$85$32,03236 claims
AstraZenecaFarxiga, Symbicort$39$12,45027 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 840 internal medicine providers in Oklahoma.

Other internal medicine in McAlester

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →